Drugs / ENT-03
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05925920 Comparator | Jun 2023 → Aug 2024 | obesity disorder, type 2 diabetes mellitus | Metabolics Pharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENT-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05925920 ↗ |
| Modality | Small molecule | — CHEMBL5314916 ↗ |
| Route | Subcutaneous | “Receive a single dose of ENT-03 sub-cutaneously” NCT05925920 ↗ |